GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (OTCPK:GALDY) » Definitions » Research & Development

GALDY (Galderma Group AG) Research & Development : $260 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Galderma Group AG's Research & Development for the six months ended in Dec. 2024 was $125 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was $260 Mil.

Galderma Group AG Research & Development Historical Data

The historical data trend for Galderma Group AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG Research & Development Chart

Galderma Group AG Annual Data
Trend Dec23 Dec24
Research & Development
287.00 260.00

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24
Research & Development 137.00 150.00 135.00 125.00

Galderma Group AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $260 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG  (OTCPK:GALDY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Galderma Group AG Research & Development Related Terms

Thank you for viewing the detailed overview of Galderma Group AG's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Galderma Group AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (OTCPK:GALDY) » Definitions » Research & Development
Comparable Companies
XSWX:SDZ XSWX:PPGN XSWX:SFZN XSWX:CURN ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN NSE:DIVISLAB HKSE:03692 XTAE:TEVA SHSE:688506 BOM:500087 TSE:4507 SZSE:000538 UTHR NSE:TORNTPHARM BOM:543904 BOM:500124
Traded in Other Exchanges
GDERF:USA GALDz:UK PY30:Germany GALD:Switzerland
Address
Zahlerweg 10, Zug, CHE, 6300
Website
https://www.galderma.com
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.